| 1.79 -0.06 (-3.24%) | 03-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.21 |
1-year : | 2.4 |
| Resists | First : | 1.89 |
Second : | 2.05 |
| Pivot price | 1.83  |
|||
| Supports | First : | 1.63 |
Second : | 1.36 |
| MAs | MA(5) : | 1.9 |
MA(20) : | 1.8 |
| MA(100) : | 1.79 |
MA(250) : | 1.8 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 50 |
D(3) : | 64.2 |
| RSI | RSI(14): 47.3 |
|||
| 52-week | High : | 3.33 | Low : | 1.22 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ OABI ] has closed above bottom band by 39.4%. Bollinger Bands are 18.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.91 - 1.93 | 1.93 - 1.93 |
| Low: | 1.74 - 1.76 | 1.76 - 1.77 |
| Close: | 1.77 - 1.79 | 1.79 - 1.81 |
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
Tue, 10 Mar 2026
OmniAb Earnings Call Highlights Platform Growth, Cash Path - The Globe and Mail
Fri, 06 Mar 2026
Benchmark Maintains Buy on OmniAb, Inc. (OABI) March 2026 - Meyka
Fri, 06 Mar 2026
OmniAb, Inc. (NASDAQ:OABI) Q4 2025 Earnings Call Transcript - Insider Monkey
Fri, 06 Mar 2026
HC Wainwright Estimates OmniAb's Q2 Earnings (NASDAQ:OABI) - MarketBeat
Thu, 05 Mar 2026
OmniAb (OABI) Q4 Revenue Surge To US$8.4 Million Tests Bearish Loss Concerns - simplywall.st
Wed, 04 Mar 2026
OmniAb Q4 Earnings Assessment - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 144 (M) |
| Shares Float | 97 (M) |
| Held by Insiders | 15.1 (%) |
| Held by Institutions | 52 (%) |
| Shares Short | 5,790 (K) |
| Shares Short P.Month | 5,920 (K) |
| EPS | -0.59 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.85 |
| Profit Margin | 0 % |
| Operating Margin | -147.4 % |
| Return on Assets (ttm) | -13.1 % |
| Return on Equity (ttm) | -23.4 % |
| Qtrly Rev. Growth | -22.5 % |
| Gross Profit (p.s.) | 0.12 |
| Sales Per Share | 0.12 |
| EBITDA (p.s.) | -0.33 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -36 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -3.04 |
| PEG Ratio | 0 |
| Price to Book value | 0.96 |
| Price to Sales | 13.8 |
| Price to Cash Flow | -7.07 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|